Overview

A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

A Phase 2 study to evaluate the safety and efficacy of two different once daily doses VX-135 in combination with ribavirin in treatment-naïve subjects with chronic hepatitis C

Phase:

Phase 2

Details

Lead Sponsor:

Vertex Pharmaceuticals Incorporated

Treatments:

Ribavirin